Credit Suisse Group set a $80.00 price target on Gilead Sciences (NASDAQ:GILD) in a report released on Wednesday. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. Vetr upgraded shares of Gilead Sciences from a buy rating to a strong-buy rating and set a $91.25 price objective for the company in a report on Monday, February 5th. Leerink Swann raised their target price on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a market perform rating in a research report on Thursday, October 19th. Citigroup reissued a buy rating and set a $105.00 target price (up previously from $103.00) on shares of Gilead Sciences in a research report on Thursday. Mizuho raised their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a buy rating in a research report on Wednesday, November 8th. Finally, Maxim Group reissued a hold rating on shares of Gilead Sciences in a research report on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Gilead Sciences has an average rating of Buy and a consensus target price of $86.56.

Shares of Gilead Sciences (NASDAQ:GILD) opened at $79.32 on Wednesday. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $89.54. The firm has a market cap of $103,590.00, a PE ratio of 22.79, a P/E/G ratio of -1.73 and a beta of 1.22. The company has a current ratio of 3.55, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same quarter last year, the business posted $2.70 EPS. The firm’s revenue for the quarter was down 18.7% on a year-over-year basis. equities analysts forecast that Gilead Sciences will post 6.46 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a $0.57 dividend. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.87%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is presently 59.77%.

In other news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the transaction, the chairman now directly owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 578,333 shares of company stock worth $44,100,508. Insiders own 1.30% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Keel Point LLC boosted its stake in Gilead Sciences by 0.4% in the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 12 shares in the last quarter. Paradigm Financial Advisors LLC boosted its stake in Gilead Sciences by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 26 shares in the last quarter. Princeton Portfolio Strategies Group LLC boosted its stake in Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after purchasing an additional 41 shares in the last quarter. Auxier Asset Management boosted its stake in Gilead Sciences by 1.4% in the 2nd quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock worth $479,000 after purchasing an additional 96 shares in the last quarter. Finally, Edmonds Duncan Registered Investment Advisors LLC boosted its stake in Gilead Sciences by 1.6% in the 2nd quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 6,386 shares of the biopharmaceutical company’s stock worth $452,000 after purchasing an additional 100 shares in the last quarter. 75.84% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/11/credit-suisse-group-reiterates-80-00-price-target-for-gilead-sciences-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.